An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine
BNT162b2, an mRNA-based SARS-CoV-2 vaccine (Pfizer-BioNTech, New York, NY, USA), is one of the most effective COVID-19 vaccines and has been approved by more than 130 countries worldwide. However, several studies have reported that the COVID-19 vaccine shows high interpersonal variability in terms o...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/4/563 |
| _version_ | 1797409026398486528 |
|---|---|
| author | Seik-Soon Khor Yosuke Omae Junko S. Takeuchi Ami Fukunaga Shohei Yamamoto Akihito Tanaka Kouki Matsuda Moto Kimura Kenji Maeda Gohzoh Ueda Tetsuya Mizoue Mugen Ujiie Hiroaki Mitsuya Norio Ohmagari Wataru Sugiura Katsushi Tokunaga |
| author_facet | Seik-Soon Khor Yosuke Omae Junko S. Takeuchi Ami Fukunaga Shohei Yamamoto Akihito Tanaka Kouki Matsuda Moto Kimura Kenji Maeda Gohzoh Ueda Tetsuya Mizoue Mugen Ujiie Hiroaki Mitsuya Norio Ohmagari Wataru Sugiura Katsushi Tokunaga |
| author_sort | Seik-Soon Khor |
| collection | DOAJ |
| description | BNT162b2, an mRNA-based SARS-CoV-2 vaccine (Pfizer-BioNTech, New York, NY, USA), is one of the most effective COVID-19 vaccines and has been approved by more than 130 countries worldwide. However, several studies have reported that the COVID-19 vaccine shows high interpersonal variability in terms of humoral and cellular responses, such as those with respect to SARS-CoV-2 spike protein immunoglobulin (Ig)G, IgA, IgM, neutralizing antibodies, and CD4<sup>+</sup> and CD8<sup>+</sup> T cells. The objective of this study is to investigate the kinetic changes in anti-SARS-CoV-2 spike IgG (IgG-S) profiles and adverse reactions and their associations with HLA profiles (<i>HLA-A</i>, <i>-C</i>, <i>-B</i>, <i>-DRB1</i>, <i>-DQA1</i>, <i>-DQB1</i>, <i>-DPA1</i> and <i>-DPB1</i>) among 100 hospital workers from the Center Hospital of the National Center for Global Health and Medicine (NCGM), Tokyo, Japan. DQA1*03:03:01 (<i>p</i> = 0.017; Odd ratio (OR) 2.80, 95%confidence interval (CI) 1.05–7.25) was significantly associated with higher IgG-S production after two doses of BNT162b2, while DQB1*06:01:01:01 (<i>p</i> = 0.028, OR 0.27, 95%CI 0.05–0.94) was significantly associated with IgG-S declines after two doses of BNT162b2. No HLA alleles were significantly associated with either local symptoms or fever. However, C*12:02:02 (<i>p</i> = 0.058; OR 0.42, 95%CI 0.15–1.16), B*52:01:01 (<i>p</i> = 0.031; OR 0.38, 95%CI 0.14–1.03), DQA1*03:02:01 (<i>p</i> = 0.028; OR 0.39, 95%CI 0.15–1.00) and DPB1*02:01:02 (<i>p</i> = 0.024; OR 0.45, 95%CI 0.21–0.97) appeared significantly associated with protection against systemic symptoms after two doses of BNT162b2 vaccination. Further studies with larger sample sizes are clearly warranted to determine HLA allele associations with the production and long-term sustainability of IgG-S after COVID-19 vaccination. |
| first_indexed | 2024-03-09T04:07:24Z |
| format | Article |
| id | doaj.art-0d6c9d5dbde64d188211cb2d406f7525 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T04:07:24Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-0d6c9d5dbde64d188211cb2d406f75252023-12-03T14:03:34ZengMDPI AGVaccines2076-393X2022-04-0110456310.3390/vaccines10040563An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA VaccineSeik-Soon Khor0Yosuke Omae1Junko S. Takeuchi2Ami Fukunaga3Shohei Yamamoto4Akihito Tanaka5Kouki Matsuda6Moto Kimura7Kenji Maeda8Gohzoh Ueda9Tetsuya Mizoue10Mugen Ujiie11Hiroaki Mitsuya12Norio Ohmagari13Wataru Sugiura14Katsushi Tokunaga15Genome Medical Science Project, National Center for Global Health and Medicine, Tokyo 162-8655, JapanGenome Medical Science Project, National Center for Global Health and Medicine, Tokyo 162-8655, JapanDepartment of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo 162-8655, JapanDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo 162-8655, JapanDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo 162-8655, JapanDepartment of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo 162-8655, JapanDepartment of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, JapanDepartment of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo 162-8655, JapanDepartment of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, JapanDivision of Core Diagnostics, Abbott Japan LLC., Tokyo 105-7115, JapanDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo 162-8655, JapanDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo 162-8655, JapanDepartment of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, JapanDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo 162-8655, JapanCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo 162-8655, JapanGenome Medical Science Project, National Center for Global Health and Medicine, Tokyo 162-8655, JapanBNT162b2, an mRNA-based SARS-CoV-2 vaccine (Pfizer-BioNTech, New York, NY, USA), is one of the most effective COVID-19 vaccines and has been approved by more than 130 countries worldwide. However, several studies have reported that the COVID-19 vaccine shows high interpersonal variability in terms of humoral and cellular responses, such as those with respect to SARS-CoV-2 spike protein immunoglobulin (Ig)G, IgA, IgM, neutralizing antibodies, and CD4<sup>+</sup> and CD8<sup>+</sup> T cells. The objective of this study is to investigate the kinetic changes in anti-SARS-CoV-2 spike IgG (IgG-S) profiles and adverse reactions and their associations with HLA profiles (<i>HLA-A</i>, <i>-C</i>, <i>-B</i>, <i>-DRB1</i>, <i>-DQA1</i>, <i>-DQB1</i>, <i>-DPA1</i> and <i>-DPB1</i>) among 100 hospital workers from the Center Hospital of the National Center for Global Health and Medicine (NCGM), Tokyo, Japan. DQA1*03:03:01 (<i>p</i> = 0.017; Odd ratio (OR) 2.80, 95%confidence interval (CI) 1.05–7.25) was significantly associated with higher IgG-S production after two doses of BNT162b2, while DQB1*06:01:01:01 (<i>p</i> = 0.028, OR 0.27, 95%CI 0.05–0.94) was significantly associated with IgG-S declines after two doses of BNT162b2. No HLA alleles were significantly associated with either local symptoms or fever. However, C*12:02:02 (<i>p</i> = 0.058; OR 0.42, 95%CI 0.15–1.16), B*52:01:01 (<i>p</i> = 0.031; OR 0.38, 95%CI 0.14–1.03), DQA1*03:02:01 (<i>p</i> = 0.028; OR 0.39, 95%CI 0.15–1.00) and DPB1*02:01:02 (<i>p</i> = 0.024; OR 0.45, 95%CI 0.21–0.97) appeared significantly associated with protection against systemic symptoms after two doses of BNT162b2 vaccination. Further studies with larger sample sizes are clearly warranted to determine HLA allele associations with the production and long-term sustainability of IgG-S after COVID-19 vaccination.https://www.mdpi.com/2076-393X/10/4/563COVID-19SARS-CoV-2Pfizer-BioNTechIgGHLAJapanese |
| spellingShingle | Seik-Soon Khor Yosuke Omae Junko S. Takeuchi Ami Fukunaga Shohei Yamamoto Akihito Tanaka Kouki Matsuda Moto Kimura Kenji Maeda Gohzoh Ueda Tetsuya Mizoue Mugen Ujiie Hiroaki Mitsuya Norio Ohmagari Wataru Sugiura Katsushi Tokunaga An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine Vaccines COVID-19 SARS-CoV-2 Pfizer-BioNTech IgG HLA Japanese |
| title | An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine |
| title_full | An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine |
| title_fullStr | An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine |
| title_full_unstemmed | An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine |
| title_short | An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine |
| title_sort | association study of hla with the kinetics of sars cov 2 spike specific igg antibody responses to bnt162b2 mrna vaccine |
| topic | COVID-19 SARS-CoV-2 Pfizer-BioNTech IgG HLA Japanese |
| url | https://www.mdpi.com/2076-393X/10/4/563 |
| work_keys_str_mv | AT seiksoonkhor anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT yosukeomae anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT junkostakeuchi anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT amifukunaga anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT shoheiyamamoto anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT akihitotanaka anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT koukimatsuda anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT motokimura anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT kenjimaeda anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT gohzohueda anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT tetsuyamizoue anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT mugenujiie anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT hiroakimitsuya anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT norioohmagari anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT watarusugiura anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT katsushitokunaga anassociationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT seiksoonkhor associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT yosukeomae associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT junkostakeuchi associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT amifukunaga associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT shoheiyamamoto associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT akihitotanaka associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT koukimatsuda associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT motokimura associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT kenjimaeda associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT gohzohueda associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT tetsuyamizoue associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT mugenujiie associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT hiroakimitsuya associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT norioohmagari associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT watarusugiura associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine AT katsushitokunaga associationstudyofhlawiththekineticsofsarscov2spikespecificiggantibodyresponsestobnt162b2mrnavaccine |